TAAR1:

Trace Amine-Associated Receptor 1




THE BURDENS OF MENTAL ILLNESS

- People with serious mental illness, such as major depressive disorder, bipolar disorder, or schizophrenia, are burdened with worse clinical outcomes and increased healthcare costs compared with people without these conditions.¹
- Some evidence shows that people with serious mental illnesses have high relapse and psychiatric hospitalization rates despite treatment with antipsychotics.^{1,2}
- When serious mental illness is present in people hospitalized for other physical conditions, they are more likely to be readmitted within 30 days.²



- TRACE AMINES TRYPTAMINE (TRYP P-TYRAMINE (TYR P-OCTOPAMINE (OCT) B-PHENYLETHYLAMINE (PEA)
- As unmet needs in schizophrenia persist, therapies with novel mechanisms of action are needed. One novel therapeutic target under investigation is TAAR1.³
- TAAR1, or trace amine-associated receptor 1, is the most studied member of the TAAR family.^{4,5} TAARs are receptors for trace amines, a type of chemical messenger found in low levels in the brain as well as in peripheral tissues.^{6,7}
- Trace amines are structurally and metabolically related to the classical monoamine neurotransmitters, dopamine, serotonin, and norepinephrine.⁸





• TAAR1 is widely distributed throughout the brain, including in dopamine and serotonin rich areas that are important to the pathophysiology of various serious mental illnesses.^{7,8}



• When activated, TAAR1 has been shown to regulate key neurotransmitters up or down to account for their state of imbalance.⁶ TAAR1's ability to regulate neurotransmitter circuits important for mood, psychosis, cognition, and reward processing, makes it a potential therapeutic target for several serious mental illnesses.⁸



FIRST AND SECOND GENERATION ANTIPSYCHOTICS

DOPAMINE RECEPTOR BLOCKING THERAPIES

MAINSTAY OF PHARMACOLOGIC TREATMENT FOR THE LAST 70 YEARS

NEW THERAPIES NEEDED

- First and second-generation antipsychotics, which work mainly by blocking dopamine receptors, have been the mainstay of pharmacologic therapy for schizophrenia for the last 70 years.
- Though effective, current therapies do not adequately treat all symptoms of schizophrenia and can be associated with side effects such as movement disorders and increased cardiometabolic risk.^{9,10,11} Novel treatment modalities that provide symptom improvement without the side effect profile of the current class are therefore needed.^{5,8,11}

References:

- 1. Ayyagari R, Thomason D, Mu F et al. Association of antipsychotic treatment switching in patients with schizophrenia, bipolar, and major depressive disorders. *J Med Econ*. 2020;23(2):204-212.
- 2. Cook JA, Burke-Miller JK, Jonikas JA et al. Factors associated with 30-day readmissions following medical hospitalizations among Medicaid beneficiaries with schizophrenia, bipolar disorder, and major depressive disorder. *Psychiatry Res.* 2020;291:113168;1-6.
- 3. Lindemann L, Hoener MC. A renaissance in trace amines inspired by a novel GPCR family. Trends Pharmacol Sci. 2005;26(5):274-281.
- 4. Revel FG, Moreau J-L, Gainetdinov RR et al. TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. *Proc Natl Acad Sci USA*. 2011;109(20):8485-8490.
- 5. Grutigliano G, Accorroni A, Zucchi R. The case for TAAR1 as a modulator of central nervous system function. Front Pharmacol. 2018;8:987.
- 6. Lindemann L, Meyer CA, Jeanneau K et al. Trace amine-associated receptor 1 modulated dopaminergic activity. J Pharmacol Exp Ther. 2008; 324(3):948-956.
- 7. Leo D, Mus L, Espinoza S et al. TAAR1-meditated modulation of presynaptic dopaminergic neurotransmission: Role of D2 dopamine autoreceptors. *Neuropharmacology*. 2014;81:283-291.
- 8. Pei Y, Asif-Malik A, Canales JJ. Trace amines and the trace amine-associated receptor 1: Pharmacology, neurochemistry, and clinical implications. *Front Neurosci.* 2016;10:148.
- 9. Berry MD, Gainetdivov RR, Hoener MC, Shahid M. Pharmacology of human trace-amine-associated receptors; Therapeutic opportunities and challenges. *Pharmacol Ther.* 2017;72(11):934-942.
- 10. Revel FG, Moreau J-L, Gainetdivov RR et al. Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics. *Biol Psychiatry*. 2012;72(11):934-942.
- Revel FG, Moreau J-L, Puzet B et al. A new perspective for schizophrenia: TAAR1 agonists reveal anti-psychotic- and antidepressant-like activity. Improve cognition and control body weight. *Mol Psychiatry*. 2013;18(5):543-556.







Scan to see the TAAR1 story come to life!

SUNOVION and 5⁴5 are registered trademarks of Sumitomo Pharma Co., Ltd. Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Sumitomo Pharma Co., Ltd. ©2022 Sunovion Pharmaceuticals Inc. All rights reserved. 5/22 NPC-ULO-US-00004-22.

